Form 8-K - Current report:
SEC Accession No. 0001213900-25-041653
Filing Date
2025-05-12
Accepted
2025-05-09 19:46:38
Documents
15
Period of Report
2025-05-09
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0241580-8k425_denali.htm   iXBRL 8-K 30112
2 PRESS RELEASE, DATED MAY 9, 2025 ea024158001ex99-1_denali.htm EX-99.1 4001
  Complete submission text file 0001213900-25-041653.txt   261203

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE dnqwf-20250509.xsd EX-101.SCH 4179
4 XBRL DEFINITION FILE dnqwf-20250509_def.xml EX-101.DEF 27310
5 XBRL LABEL FILE dnqwf-20250509_lab.xml EX-101.LAB 37896
6 XBRL PRESENTATION FILE dnqwf-20250509_pre.xml EX-101.PRE 25930
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0241580-8k425_denali_htm.xml XML 6845
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25932234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)